| Literature DB >> 17784729 |
Chidambaram Gunanathan1, Adi Pais, Edna Furman-Haran, Dalia Seger, Erez Eyal, Sarbani Mukhopadhyay, Yehoshoa Ben-David, Gregory Leitus, Hagai Cohen, Ayelet Vilan, Hadassa Degani, David Milstein.
Abstract
Novel estrogen-conjugated pyridine-containing Gd(III) and Eu(III) contrast agents (EPTA-Gd/Eu) were designed and effectively synthesized. Convenient to administration and MRI experiments, both EPTA-Gd and EPTA-Eu are soluble in water. The EPTA-Gd selectively binds with a micromolar affinity to the estrogen receptor and induces proliferation of human breast cancer cells. The EPTA-Gd is not lethal and does not cause any adverse effects when administrated intravenously. It enhances T1 and T2 nuclear relaxation rates of water and serves as a selective contrast agent for localizing the estrogen receptor by MRI.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17784729 DOI： 10.1021/bc700230m
Source DB: PubMed Journal: Bioconjug Chem ISSN： 1043-1802 Impact factor: 4.774